Goji Hasegawa Selected Research

gluconolactonase

1/2015	Senescence marker protein-30/gluconolactonase deficiency exacerbates diabetic nephropathy through tubular injury in a mouse model of type 1 diabetes.
3/2012	Pancreatic insulin release in vitamin C-deficient senescence marker protein-30/gluconolactonase knockout mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Goji Hasegawa Research Topics

Disease

58	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2002
18	Cardiovascular Diseases (Cardiovascular Disease) 07/2015 - 06/2003
14	Diabetic Nephropathies (Diabetic Nephropathy) 11/2019 - 09/2002
13	Atherosclerosis 05/2015 - 01/2006
11	Albuminuria 01/2016 - 09/2007
11	Insulin Resistance 03/2012 - 01/2004
9	Hyperglycemia 01/2020 - 01/2004
7	Diabetes Mellitus 12/2019 - 08/2002
7	Endometriosis 12/2007 - 01/2002
5	Hypertension (High Blood Pressure) 06/2014 - 12/2006
5	Genetic Predisposition to Disease (Genetic Predisposition) 12/2007 - 01/2002
3	Obesity 09/2015 - 01/2004
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2015 - 03/2010
3	Diabetes Complications 01/2014 - 07/2008
3	Glucose Intolerance 03/2012 - 03/2008
3	Non-alcoholic Fatty Liver Disease 01/2011 - 04/2010
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2011 - 08/2003
3	Carotid Artery Diseases 02/2008 - 06/2003
3	Body Weight (Weight, Body) 10/2005 - 01/2004
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 02/2003
2	Coronary Artery Disease (Coronary Atherosclerosis) 05/2015 - 07/2012
2	Dyslipidemias (Dyslipidemia) 06/2014 - 03/2012
2	Inflammation (Inflammations) 01/2014 - 03/2010
2	Fatty Liver 01/2013 - 01/2011
2	Atrophic Gastritis 07/2012 - 04/2012
2	Overnutrition 04/2012 - 03/2010
2	Hyperinsulinism (Hyperinsulinemia) 03/2011 - 10/2010
2	Hyperlipidemias (Hyperlipidemia) 06/2010 - 02/2007
2	Infections 12/2009 - 12/2008
2	Bone Resorption 07/2008 - 09/2007
2	Hypogonadism (Hypergonadotropic Hypogonadism) 03/2008 - 02/2007
1	Hypoglycemia (Reactive Hypoglycemia) 01/2021

Drug/Important Bio-Agent (IBA)

25	AlbuminsIBA 11/2019 - 01/2004
15	LipidsIBA 03/2013 - 06/2003
13	Hemoglobins (Hemoglobin)IBA 12/2019 - 03/2008
11	CreatinineIBA 12/2019 - 08/2012
9	Glucose (Dextrose)FDA LinkGeneric 04/2015 - 01/2004
8	Insulin (Novolin)FDA Link 01/2021 - 07/2005
7	Testosterone (Sustanon)FDA Link 12/2008 - 06/2003
6	Uric Acid (Urate)IBA 04/2015 - 05/2008
5	Triglycerides (Triacylglycerol)IBA 06/2014 - 01/2011
5	Dehydroepiandrosterone (DHEA)IBA 07/2008 - 12/2004
5	Dehydroepiandrosterone SulfateIBA 09/2007 - 12/2004
4	Blood Glucose (Blood Sugar)IBA 01/2021 - 01/2004
4	CholesterolIBA 12/2019 - 01/2011
4	Indicators and Reagents (Reagents)IBA 11/2019 - 07/2008
4	Proteins (Proteins, Gene)FDA Link 01/2015 - 01/2006
4	BilirubinIBA 06/2014 - 11/2008
4	Biomarkers (Surrogate Marker)IBA 03/2013 - 12/2006
4	Lipoproteins (Lipoprotein)IBA 01/2013 - 04/2008
4	C-Reactive ProteinIBA 01/2013 - 12/2008
4	Hemoglobin AIBA 12/2012 - 09/2007
4	AndrogensIBA 12/2007 - 02/2007
3	Antihypertensive Agents (Antihypertensives)IBA 11/2019 - 12/2012
3	AcidsIBA 07/2015 - 10/2007
3	glimepiride (Amarel)FDA LinkGeneric 01/2014 - 10/2005
3	Pepsinogen A (Pepsinogen)IBA 01/2013 - 04/2012
3	oxidized low density lipoproteinIBA 01/2013 - 01/2010
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2013 - 11/2010
3	nasIBA 01/2011 - 04/2010
3	CytokinesIBA 12/2009 - 08/2004
3	AntibodiesIBA 12/2008 - 01/2004
2	repaglinide (Prandin)FDA Link 01/2020 - 01/2014
2	SaltsIBA 01/2017 - 12/2012
2	Metformin (Glucophage)FDA LinkGeneric 05/2016 - 01/2010
2	CarbohydratesIBA 07/2015 - 01/2011
2	gluconolactonaseIBA 01/2015 - 03/2012
2	Angiotensin Receptor AntagonistsIBA 06/2014 - 09/2007
2	LDL CholesterolIBA 12/2012 - 01/2011
2	Hydroxyindoleacetic AcidIBA 01/2012 - 08/2009
2	Serotonin (5 Hydroxytryptamine)IBA 01/2012 - 08/2009
2	Ezetimibe (Zetia)FDA Link 01/2011 - 11/2010
2	LDL Lipoproteins (beta Lipoproteins)IBA 04/2010 - 04/2008
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2010 - 10/2005
2	AdiponectinIBA 01/2010 - 12/2006
2	HLA Antigens (Human Leukocyte Antigens)IBA 12/2009 - 02/2003
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2009 - 03/2008
2	Collagen Type I (Type I Collagen)IBA 07/2008 - 09/2007
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 07/2008 - 02/2007
2	Retinaldehyde (Retinal)IBA 09/2007 - 08/2003
2	CollagenIBA 09/2007 - 01/2006
2	Advanced Glycation End ProductsIBA 09/2007 - 08/2003
2	pentosidineIBA 09/2007 - 08/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2006 - 05/2004
2	Interleukin-6 (Interleukin 6)IBA 10/2006 - 08/2003
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2006 - 01/2004
2	ResistinIBA 01/2006 - 01/2004
2	8-Hydroxy-2'-DeoxyguanosineIBA 01/2005 - 01/2004
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 05/2004 - 02/2003
2	ImmunosorbentsIBA 01/2004 - 04/2003
2	EnzymesIBA 01/2004 - 04/2003
2	astaxanthine (astaxanthin)IBA 01/2004 - 01/2002
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021
1	dapagliflozinIBA 01/2021
1	voglibose (Basen)IBA 01/2020
1	mitiglinideIBA 01/2020
1	Vasopressins (Vasopressin)IBA 01/2017

Therapy/Procedure

12	Glycemic Control 08/2014 - 12/2004
4	Therapeutics 09/2015 - 10/2005
1	Drug Tapering 01/2021